Doctors across multiple countries are flagging a painful new COVID-19 symptom tied to a fast-spreading variant: a sore throat ...

A Nova Scotian book publisher says the provincial government's cuts to the arts and culture sector are "soul-crushing" when sales have already been decimated by uncertainty in the U.S. market.

A Nova Scotian book publisher says the provincial government’s cuts to the arts and culture sector are “soul-crushing” when ...

Nimbus Group has appointed Christian Johansson as interim chief financial officer (CFO), effective 1 March. Throughout March, Johansson will work alongside the current CFO, Rasmus Alvemyr, who ...

Baird debuts with a caustic send-up of the campus novel centered on a divinity professor’s attempt to cash in on a strange phenomenon involving his toddler. Adrian Bennett’s two-year-old son, Luca, ...

The Gel-Nimbus 27 is built for maximum cushioning, featuring ASICS’ unique FF BLAST PLUS midsole foam made with bio-based materials for a lighter, softer landing. PureGEL technology in the heel helps ...

Apple Notes is a versatile and powerful tool that goes far beyond basic note-taking. With its seamless integration across Apple devices and a host of advanced features, it can significantly enhance ...

Nimbus Therapeutics announced a collaboration with Eli Lilly to create innovative AI-driven oral treatments for obesity and other metabolic diseases. This pioneering research and licensing agreement ...

Jan 6 (Reuters) - Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement with Eli Lilly (LLY.N), opens new tab to develop artificial intelligence-driven ...

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases. Nimbus, an ...

Boston biotech Nimbus Therapeutics is teaming up with Eli Lilly & Co. to develop a new oral obesity treatment in a deal worth up to $1.3 billion, the company announced Tuesday. It’s the latest move in ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space of oral obesity therapies. The latest partnership will see Lilly pass ...